Rhumbline Advisers Acquires 5,833 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Rhumbline Advisers increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 410,508 shares of the biopharmaceutical company’s stock after purchasing an additional 5,833 shares during the period. Rhumbline Advisers’ holdings in Halozyme Therapeutics were worth $19,626,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Heck Capital Advisors LLC bought a new position in Halozyme Therapeutics in the fourth quarter valued at about $29,000. CWM LLC increased its stake in shares of Halozyme Therapeutics by 77.5% in the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 668 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Halozyme Therapeutics by 173.6% in the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,028 shares during the period. Centaurus Financial Inc. acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $127,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $150,000. 97.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HALO shares. HC Wainwright increased their price target on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Finally, Benchmark reaffirmed a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 0.6 %

Shares of Halozyme Therapeutics stock opened at $57.44 on Friday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a 52 week low of $36.61 and a 52 week high of $65.53. The stock has a 50 day moving average price of $53.26 and a two-hundred day moving average price of $54.58. The stock has a market capitalization of $7.31 billion, a PE ratio of 16.75, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 165.13% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.72 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.